BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 17692976)

  • 21. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
    Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colorectal complications of external beam radiation versus brachytherapy for prostate cancer.
    Lesperance RN; Kjorstadt RJ; Halligan JB; Steele SR
    Am J Surg; 2008 May; 195(5):616-20; discussion 620. PubMed ID: 18374892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101).
    Rancati T; Fiorino C; Gagliardi G; Cattaneo GM; Sanguineti G; Borca VC; Cozzarini C; Fellin G; Foppiano F; Girelli G; Menegotti L; Piazzolla A; Vavassori V; Valdagni R
    Radiother Oncol; 2004 Oct; 73(1):21-32. PubMed ID: 15465142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients.
    Goldner G; Tomicek B; Becker G; Geinitz H; Wachter S; Zimmermann F; Wachter-Gerstner N; Reibenwein J; Glocker S; Bamberg M; Feldmann H; Pötzi R; Molls M; Pötter R
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):78-83. PubMed ID: 17189064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
    Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
    Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer.
    Wilder RB; Barme GA; Gilbert RF; Holevas RE; Kobashi LI; Reed RR; Solomon RS; Walter NL; Chittenden L; Mesa AV; Agustin J; Lizarde J; Macedo J; Ravera J; Tokita KM
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):824-30. PubMed ID: 20510195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
    Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
    Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of adjuvant treatment of endometrial cancer using aperture-based intensity-modulated radiotherapy.
    Bouchard M; Nadeau S; Gingras L; Raymond PE; Beaulieu F; Beaulieu L; Fortin A; Germain I
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1343-50. PubMed ID: 18294780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.
    Ghadjar P; Matzinger O; Isaak B; Behrensmeier F; Stroux A; Rentsch CA; Thalmann GN; Aebersold DM
    Radiother Oncol; 2009 May; 91(2):237-42. PubMed ID: 19167121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
    Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
    Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer.
    Di Muzio N; Fiorino C; Cozzarini C; Alongi F; Broggi S; Mangili P; Guazzoni G; Valdagni R; Calandrino R; Fazio F
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):392-8. PubMed ID: 19056184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study.
    Marchand V; Bourdin S; Charbonnel C; Rio E; Munos C; Campion L; Bonnaud-Antignac A; Lisbona A; Mahé MA; Supiot S
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1053-9. PubMed ID: 19880259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.
    Vavassori V; Fiorino C; Rancati T; Magli A; Fellin G; Baccolini M; Bianchi C; Cagna E; Mauro FA; Monti AF; Munoz F; Stasi M; Franzone P; Valdagni R
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1401-10. PubMed ID: 17241754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer.
    Chan LW; Xia P; Gottschalk AR; Akazawa M; Scala M; Pickett B; Hsu IC; Speight J; Roach M
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):69-77. PubMed ID: 18342454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study.
    Fiorino C; Fellin G; Rancati T; Vavassori V; Bianchi C; Borca VC; Girelli G; Mapelli M; Menegotti L; Nava S; Valdagni R
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1130-7. PubMed ID: 17881142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.